Mark A Dickson, ASCO 2026: Abemaciclib Brings Marked Increase in Progression Free Survival for Patients with Advanced Dedifferentiated Liposarcoma

Mark A Dickson, ASCO 2026: Abemaciclib Brings Marked Increase in Progression Free Survival for Patients with Advanced Dedifferentiated Liposarcoma

June 15, 2026 · 7 min

About this episode

An interview with Mark A Dickson discussing the impact of Abemaciclib on progression free survival in patients with advanced dedifferentiated liposarcoma.

Abemaciclib Brings Marked Increase in Progression Free Survival for Patients with Advanced Dedifferentiated Liposarcoma An interview with: Mark A Dickson MD, Medical Oncologist, Associate Attending Ph

People in this episode

Guest: Mark A Dickson

Topics covered

Keywords

Mentioned in this episode

Organizations: ASCO

Products: Abemaciclib

Places: Advanced Dedifferentiated Liposarcoma

More episodes of Audio Journal of Oncology Podcast

Explore listener stats, chart rankings, contacts and more on the Audio Journal of Oncology Podcast podcast page.